Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Taylor

Showing results (131-140 of 246) with videos related to

Pageof 25
Sort By:
Advances in Therapy|September 5, 2022
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19Thomas Bieber, Eugen Feist, Alan D Irvine, et al.
Rheumatology and Therapy|January 9, 2020
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b TrialsJacqueline M Tarrant, René Galien, Wanying Li, et al.
The Journal of Rheumatology|August 17, 2017
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid ArthritisEdward C Keystone, Mark C Genovese, Douglas E Schlichting, et al.
Rheumatology and Therapy|November 20, 2023
Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to MethotrexateYoshiya Tanaka, Peter C Taylor, Emon Elboudwarej, et al.
Rheumatology and Therapy|July 25, 2023
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to MethotrexateYoshiya Tanaka, Peter C Taylor, Emon Elboudwarej, et al.
Biomedicines|November 27, 2021
Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic InsultOzlem Ozen Karakus, Noureldien H E Darwish, Thangirala Sudha, et al.
Biomedicines|June 24, 2022
Correction: Karakus et al. Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult. <i>Biomedicines</i> 2021, <i>9</i>, 1713Ozlem Ozen Karakus, Noureldien H E Darwish, Thangirala Sudha, et al.
Trials|March 24, 2019
Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementationClifton O Bingham, Carol L Gaich, Amy M DeLozier, et al.
European Journal of Radiology|April 9, 2013
Evaluating automated dynamic contrast enhanced wrist 3T MRI in healthy volunteers: one-year longitudinal observational studyAnshul Rastogi, Olga Kubassova, Lada V Krasnosselskaia, et al.
Annals of the Rheumatic Diseases|September 18, 2012
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitisEjaz Pathan, Sonya Abraham, Elizabeth Van Rossen, et al.
Pageof 25

Showing results (131-140 of 246) with videos related to

Sort By:
Pageof 25
Advances in Therapy|September 5, 2022
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19Thomas Bieber, Eugen Feist, Alan D Irvine, et al.
Rheumatology and Therapy|January 9, 2020
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b TrialsJacqueline M Tarrant, René Galien, Wanying Li, et al.
The Journal of Rheumatology|August 17, 2017
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid ArthritisEdward C Keystone, Mark C Genovese, Douglas E Schlichting, et al.
Rheumatology and Therapy|November 20, 2023
Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to MethotrexateYoshiya Tanaka, Peter C Taylor, Emon Elboudwarej, et al.
Rheumatology and Therapy|July 25, 2023
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to MethotrexateYoshiya Tanaka, Peter C Taylor, Emon Elboudwarej, et al.
Biomedicines|November 27, 2021
Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic InsultOzlem Ozen Karakus, Noureldien H E Darwish, Thangirala Sudha, et al.
Biomedicines|June 24, 2022
Correction: Karakus et al. Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult. <i>Biomedicines</i> 2021, <i>9</i>, 1713Ozlem Ozen Karakus, Noureldien H E Darwish, Thangirala Sudha, et al.
Trials|March 24, 2019
Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementationClifton O Bingham, Carol L Gaich, Amy M DeLozier, et al.
European Journal of Radiology|April 9, 2013
Evaluating automated dynamic contrast enhanced wrist 3T MRI in healthy volunteers: one-year longitudinal observational studyAnshul Rastogi, Olga Kubassova, Lada V Krasnosselskaia, et al.
Annals of the Rheumatic Diseases|September 18, 2012
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitisEjaz Pathan, Sonya Abraham, Elizabeth Van Rossen, et al.
Pageof 25